Your browser doesn't support javascript.
loading
Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC.
Luo, Yuejun; Sun, Nan; He, Jie.
Affiliation
  • Luo Y; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
  • Sun N; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • He J; Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China. sunnan@vip.126.com.
Signal Transduct Target Ther ; 7(1): 169, 2022 05 25.
Article in En | MEDLINE | ID: mdl-35614047
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Nivolumab Type of study: Guideline Language: En Journal: Signal Transduct Target Ther Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Nivolumab Type of study: Guideline Language: En Journal: Signal Transduct Target Ther Year: 2022 Document type: Article Affiliation country: